Harvard Apparatus Regenerative Technology treats first patient in Phase 1 esophageal implant trial

Harvard Apparatus Regenerative Technology, Inc.

First patient treated with Cellspan Esophageal Implant (CEI) in Phase 1 clinical trial at Mayo Clinic.
Phase 1 trial is a feasibility and safety study in up to 10 patients under an FDA-approved IND, with three active clinical sites.
Primary endpoint: establishment of a continuous biological neoconduit by three months post-surgery; secondary: mucosal lining by 12 months.
CEI combines a polyurethane scaffold with autologous adipose-derived mesenchymal stromal cells; scaffold removed endoscopically at 21-42 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.